Timetable: Initial (full) marketing authorisation application assessment
Submitted by Anonymous (not verified) on 19 April 2024 - 10:00
Timetable: Initial (full) marketing authorisation application assessment
Timetable: Informed consent and multiple application
Submitted by Anonymous (not verified) on 19 April 2024 - 10:00
Timetable: Informed consent and multiple application
Timetable: Initial (full) marketing authorisation application assessment
Submitted by Anonymous (not verified) on 19 April 2024 - 10:00
Timetable: Initial (full) marketing authorisation application assessment
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)
Submitted by Anonymous (not verified) on 18 April 2024 - 16:31
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)
Timetable: Extension application
Submitted by Anonymous (not verified) on 18 April 2024 - 16:20
Timetable: Extension application
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables
Submitted by Anonymous (not verified) on 18 April 2024 - 15:43
Timetable: Initial (full) marketing authorisation application accelerated assessment timetables
Timetable accelerated assessment request for initial marketing authorisation applications
Submitted by Anonymous (not verified) on 18 April 2024 - 15:29
Timetable accelerated assessment request for initial marketing authorisation applications
Timetable: Extension application - ATMP
Submitted by Anonymous (not verified) on 18 April 2024 - 15:00
Timetable: Extension application - ATMP
Timetable: Companion diagnostic initial consultation - ATMP
Submitted by Anonymous (not verified) on 18 April 2024 - 14:47
Timetable: Companion diagnostic initial consultation - ATMP
Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 8, Status: Authorised
Submitted by Anonymous (not verified) on 18 April 2024 - 13:57
Human medicines European public assessment report (EPAR): Alymsys, bevacizumab, Date of authorisation: 26/03/2021, Revision: 8, Status: Authorised